182 related articles for article (PubMed ID: 25677219)
1. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.
Devriese LA; Witteveen PE; Mergui-Roelvink M; Smith DA; Lewis LD; Mendelson DS; Bang YJ; Chung HC; Dar MM; Huitema AD; Beijnen JH; Voest EE; Schellens JH
Br J Clin Pharmacol; 2015 Aug; 80(2):253-66. PubMed ID: 25677219
[TBL] [Abstract][Full Text] [Related]
2. Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers.
Li N; Song Y; Du P; Shen Y; Yang J; Gui L; Wang S; Wang J; Sun Y; Han X; Shi Y
Biomed Pharmacother; 2013 Oct; 67(8):801-6. PubMed ID: 24074809
[TBL] [Abstract][Full Text] [Related]
3. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
Gerrits CJ; Burris H; Schellens JH; Planting AS; van den Burg ME; Rodriguez GI; van Beurden V; Loos WJ; Hudson I; Fields S; Verweij J; von Hoff DD
Eur J Cancer; 1998 Jun; 34(7):1030-5. PubMed ID: 9849451
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
[TBL] [Abstract][Full Text] [Related]
5. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
6. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
Schneider CP; Merkel U; Grübner U; Kath R; Höffken K; Hoffmann A
J Cancer Res Clin Oncol; 2002 Jun; 128(6):313-8. PubMed ID: 12073049
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
9. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.
Andreopoulou E; Chen T; Liebes L; Curtin J; Blank S; Wallach R; Hochster H; Muggia F
Cancer Chemother Pharmacol; 2011 Aug; 68(2):457-63. PubMed ID: 21069334
[TBL] [Abstract][Full Text] [Related]
10. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacologic study of topotecan in patients with impaired renal function.
O'Reilly S; Rowinsky EK; Slichenmyer W; Donehower RC; Forastiere AA; Ettinger DS; Chen TL; Sartorius S; Grochow LB
J Clin Oncol; 1996 Dec; 14(12):3062-73. PubMed ID: 8955651
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of docetaxel and topotecan in patients with solid tumors.
Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
15. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
Daw NC; Santana VM; Iacono LC; Furman WL; Hawkins DR; Houghton PJ; Panetta JC; Gajjar AJ; Stewart CF
J Clin Oncol; 2004 Mar; 22(5):829-37. PubMed ID: 14990638
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
18. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
[TBL] [Abstract][Full Text] [Related]
19. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.
de Jonge MJ; Loos WJ; Gelderblom H; Planting AS; van der Burg ME; Sparreboom A; Brouwer E; van Beurden V; Mantel MA; Doyle E; Hearn S; Ross G; Verweij J
J Clin Oncol; 2000 May; 18(10):2104-15. PubMed ID: 10811676
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Kummar S; Chen A; Ji J; Zhang Y; Reid JM; Ames M; Jia L; Weil M; Speranza G; Murgo AJ; Kinders R; Wang L; Parchment RE; Carter J; Stotler H; Rubinstein L; Hollingshead M; Melillo G; Pommier Y; Bonner W; Tomaszewski JE; Doroshow JH
Cancer Res; 2011 Sep; 71(17):5626-34. PubMed ID: 21795476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
